SRNE logo

Sorrento Therapeutics (SRNE) Cash From Financing

Annual CFF

$311.72 M
+$130.39 M+71.90%

December 31, 2022


Summary


Performance

SRNE Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSRNEcash flowmetrics:

Quarterly CFF

$88.81 M
+$27.62 M+45.13%

June 30, 2023


Summary


Performance

SRNE Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSRNEcash flowmetrics:

TTM CFF

$246.59 M
+$47.04 M+23.57%

June 30, 2023


Summary


Performance

SRNE TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSRNEcash flowmetrics:

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

SRNE Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+71.9%+45.1%+23.6%
3 y3 years+295.1%+45.1%+23.6%
5 y5 years+480.8%+45.1%+23.6%

SRNE Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+71.9%-48.8%+254.1%-31.0%+36.0%
5 y5-yearat high+295.1%-48.8%+867.2%-31.0%+212.6%
alltimeall time-4.4%+9413.4%-48.8%+495.0%-31.0%+7467.4%

Sorrento Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2023
-
$88.81 M(+45.1%)
$246.59 M(+23.6%)
Mar 2023
-
$61.20 M(+144.0%)
$199.54 M(-36.0%)
Dec 2022
$311.72 M(+71.9%)
$25.08 M(-64.9%)
$311.72 M(-12.8%)
Sep 2022
-
$71.50 M(+71.2%)
$357.50 M(+9.6%)
Jun 2022
-
$41.77 M(-75.9%)
$326.06 M(+2.1%)
Mar 2022
-
$173.37 M(+144.7%)
$319.34 M(+76.1%)
Dec 2021
$181.33 M(+4.1%)
$70.86 M(+76.9%)
$181.33 M(+83.4%)
Sep 2021
-
$40.06 M(+14.3%)
$98.90 M(-44.0%)
Jun 2021
-
$35.06 M(-0.8%)
$176.69 M(-4.4%)
Mar 2021
-
$35.36 M(-405.4%)
$184.87 M(+6.1%)
Dec 2020
$174.24 M(+120.9%)
-$11.58 M(-109.8%)
$174.24 M(-22.1%)
Sep 2020
-
$117.85 M(+172.6%)
$223.72 M(+74.2%)
Jun 2020
-
$43.24 M(+74.9%)
$128.44 M(+22.7%)
Mar 2020
-
$24.72 M(-34.8%)
$104.70 M(+32.7%)
Dec 2019
$78.89 M(-75.8%)
$37.91 M(+68.0%)
$78.89 M(-36.5%)
Sep 2019
-
$22.57 M(+15.7%)
$124.27 M(-53.8%)
Jun 2019
-
$19.50 M(-1877.8%)
$269.00 M(-9.3%)
Mar 2019
-
-$1.10 M(-101.3%)
$296.67 M(-9.0%)
Dec 2018
$326.00 M(+507.4%)
$83.30 M(-50.2%)
$326.00 M(+20.2%)
Sep 2018
-
$167.30 M(+254.7%)
$271.22 M(+156.0%)
Jun 2018
-
$47.17 M(+67.1%)
$105.96 M(+1.5%)
Mar 2018
-
$28.23 M(-1.0%)
$104.39 M(+94.5%)
Dec 2017
$53.67 M(-59.3%)
$28.51 M(+1293.6%)
$53.67 M(-23.6%)
Sep 2017
-
$2.05 M(-95.5%)
$70.29 M(+15.0%)
Jun 2017
-
$45.60 M(-302.8%)
$61.12 M(-42.7%)
Mar 2017
-
-$22.48 M(-149.8%)
$106.70 M(-19.0%)
Dec 2016
$131.74 M(-4036.1%)
$45.13 M(-733.5%)
$131.74 M(+55.9%)
Sep 2016
-
-$7.12 M(-107.8%)
$84.50 M(-7.2%)
Jun 2016
-
$91.18 M(+3465.7%)
$91.04 M(<-9900.0%)
Mar 2016
-
$2.56 M(-221.2%)
-$79.00 K(-97.6%)
Dec 2015
-$3.35 M(-104.2%)
-$2.11 M(+260.1%)
-$3.35 M(-107.6%)
Sep 2015
-
-$586.00 K(-1076.7%)
$44.21 M(-1.2%)
Jun 2015
-
$60.00 K(-108.4%)
$44.74 M(-37.3%)
Mar 2015
-
-$711.00 K(-101.6%)
$71.38 M(-10.3%)
Dec 2014
$79.59 M
$45.45 M(<-9900.0%)
$79.59 M(+20.0%)
Sep 2014
-
-$55.00 K(-100.2%)
$66.35 M(-6.0%)
Jun 2014
-
$26.70 M(+256.0%)
$70.58 M(+61.0%)
DateAnnualQuarterlyTTM
Mar 2014
-
$7.50 M(-76.7%)
$43.83 M(+0.6%)
Dec 2013
$43.57 M(+629.8%)
$32.21 M(+671.8%)
$43.57 M(+282.4%)
Sep 2013
-
$4.17 M(-8616.3%)
$11.39 M(+57.8%)
Jun 2013
-
-$49.00 K(-100.7%)
$7.22 M(-45.3%)
Mar 2013
-
$7.24 M(>+9900.0%)
$13.21 M(+121.2%)
Dec 2012
$5.97 M(+200.9%)
$31.80 K(>+9900.0%)
$5.97 M(-24.6%)
Sep 2012
-
$0.00(-100.0%)
$7.91 M(0.0%)
Jun 2012
-
$5.94 M(>+9900.0%)
$7.91 M(+298.9%)
Mar 2012
-
$0.00(-100.0%)
$1.98 M(0.0%)
Dec 2011
$1.98 M(-42.3%)
$1.98 M(>+9900.0%)
$1.98 M(-42.5%)
Sep 2011
-
$0.00(-100.0%)
$3.45 M(0.0%)
Jun 2011
-
$7900.00(>+9900.0%)
$3.45 M(+0.2%)
Mar 2011
-
$0.00(-100.0%)
$3.44 M(0.0%)
Dec 2010
$3.44 M(-16.2%)
$3.44 M(>+9900.0%)
$3.44 M(>+9900.0%)
Sep 2010
-
$0.00(0.0%)
$1600.00(-99.9%)
Jun 2010
-
$0.00(0.0%)
$1.83 M(-55.4%)
Mar 2010
-
$0.00(-100.0%)
$4.11 M(0.0%)
Dec 2009
$4.11 M(>+9900.0%)
$1600.00(-99.9%)
$4.11 M(+15.9%)
Sep 2009
-
$1.83 M(-19.6%)
$3.54 M(+55.7%)
Jun 2009
-
$2.27 M(-504.3%)
$2.27 M(>+9900.0%)
Dec 2008
$0.00(-100.0%)
-$562.50 K(-200.0%)
$0.00(-100.0%)
Sep 2008
-
$562.50 K(>+9900.0%)
$562.50 K(>+9900.0%)
Jun 2008
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2008
-
$0.00(0.0%)
$0.00(-100.0%)
Dec 2007
$690.00 K(>+9900.0%)
$0.00(0.0%)
$690.00 K(0.0%)
Sep 2007
-
$0.00(0.0%)
$690.00 K(0.0%)
Jun 2007
-
$0.00(-100.0%)
$690.00 K(0.0%)
Mar 2007
-
$690.00 K(-7363.2%)
$690.00 K(-7363.2%)
Dec 2006
$0.00(-100.0%)
-
-
Dec 2005
-$9500.00(<-9900.0%)
-$9500.00(<-9900.0%)
-$9500.00(<-9900.0%)
Sep 2005
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2005
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2005
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2004
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2004
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2004
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2004
-
$0.00
$0.00
Dec 2003
$0.00
-
-

FAQ

  • What is Sorrento Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Sorrento Therapeutics?
  • What is Sorrento Therapeutics annual CFF year-on-year change?
  • What is Sorrento Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Sorrento Therapeutics?
  • What is Sorrento Therapeutics quarterly CFF year-on-year change?
  • What is Sorrento Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Sorrento Therapeutics?
  • What is Sorrento Therapeutics TTM CFF year-on-year change?

What is Sorrento Therapeutics annual cash flow from financing activities?

The current annual CFF of SRNE is $311.72 M

What is the all time high annual CFF for Sorrento Therapeutics?

Sorrento Therapeutics all-time high annual cash flow from financing activities is $326.00 M

What is Sorrento Therapeutics annual CFF year-on-year change?

Over the past year, SRNE annual cash flow from financing activities has changed by +$130.39 M (+71.90%)

What is Sorrento Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of SRNE is $88.81 M

What is the all time high quarterly CFF for Sorrento Therapeutics?

Sorrento Therapeutics all-time high quarterly cash flow from financing activities is $173.37 M

What is Sorrento Therapeutics quarterly CFF year-on-year change?

Over the past year, SRNE quarterly cash flow from financing activities has changed by +$27.62 M (+45.13%)

What is Sorrento Therapeutics TTM cash flow from financing activities?

The current TTM CFF of SRNE is $246.59 M

What is the all time high TTM CFF for Sorrento Therapeutics?

Sorrento Therapeutics all-time high TTM cash flow from financing activities is $357.50 M

What is Sorrento Therapeutics TTM CFF year-on-year change?

Over the past year, SRNE TTM cash flow from financing activities has changed by +$47.04 M (+23.57%)